Simultaneous loss of phospholipase Cδ1 and phospholipase Cδ3 causes cardiomyocyte apoptosis and cardiomyopathy

Y Nakamura1,2, K Kanemaru1,2, R Kojima1, Y Hashimoto1, T Marunouchi3, N Oka1, T Ogura1, K Tanonaka3 and K Fukami*1,2

Phospholipase C (PLC) is a key enzyme in phosphoinositide turnover. Among 13 PLC isozymes, PLCδ1 and PLCδ3 share high sequence homology and similar tissue distribution, and are expected to have functional redundancy in many tissues. We previously reported that the simultaneous loss of PLCδ1 and PLCδ3 caused embryonic lethality because of excessive apoptosis and impaired vascularization of the placenta. Prenatal death of PLCδ1/PLCδ3 double-knockout mice hampered our investigation of the roles of these genes in adult animals. Here, we generated PLCδ1/PLCδ3 double-knockout mice that expressed PLCδ1 in extra-embryonic tissues (cDKO mice) to escape embryonic lethality. The cDKO mice were born at the expected Mendelian ratio, which indicated that the simultaneous loss of PLCδ1 and PLCδ3 in the embryo proper did not impair embryonic development. However, half of the cDKO mice died prematurely. In addition, the surviving cDKO mice spontaneously showed cardiac abnormalities, such as increased heart weight/tibial length ratios, impaired cardiac function, cardiac fibrosis, dilation, and hypertrophy. Predating these abnormalities, excessive apoptosis of their cardiomyocytes was observed. In addition, siRNA-mediated simultaneous silencing of PLCδ1 and PLCδ3 increased apoptosis in differentiated-H9c2 cardiomyoblasts. Activation of Akt and protein kinase C (PKC) θ was impaired in the hearts of the cDKO mice. siRNA-mediated simultaneous silencing of PLCδ1 and PLCδ3 also decreased activated Akt and PKCθ in differentiated-H9c2 cardiomyoblasts. These results indicate that PLCδ1 and PLCδ3 are required for cardiomyocyte survival and normal cardiac function.

Cell Death and Disease (2014) 5, e1215; doi:10.1038/cddis.2014.181; published online 8 May 2014

Subject Category: Experimental Medicine

Dilated cardiomyopathy (DCM) is the most common type of non-ischemic cardiomyopathy, and is characterized by myocardial contractile dysfunction and cardiac diameter enlargement, which leads to heart failure. DCM is often accompanied by pathological remodeling, such as cardiac fibrosis and hypertrophy. In addition, apoptotic cardiomyocytes are observed in the hearts of humans with DCM.1–3 Interestingly, cardiomyocyte apoptosis was reported to be sufficient to induce adverse cardiac remodeling in an animal model.4 Phospholipase C (PLC) is a key enzyme in phosphoinositide turnover. PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate two second messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol.5,6 There are PLC isoform.9 We previously reported that the loss of PLCδ1 and PLCδ3 share high sequence homology and similar tissue distribution, and are expected to have functional redundancy in many tissues. Disruption of the PLCδ1 gene also protects mice from obesity by inhibiting lipid accumulation in adipose tissue.14 Regarding PLCδ3, siRNA-mediated silencing of PLCδ3 inhibits neuronal migration and neurite outgrowth.15 PLCδ1 and PLCδ3 are expressed in the heart, in addition to the skin, adipose, and neuronal tissues, and are expected to have critical roles in the cardiovascular system. The downstream effector of PLC, protein kinase C (PKC) has critical roles in cardiac structure and function. Several PKC isozymes are expressed in cardiomyocytes and regulate cardiac responses.16 Overexpression of PKCζ in cultured cardiomyocytes induces hypertrophy.17 On the other hand, loss of PKCζ prevents the transition from cardiac hypertrophy to cardiac failure.18 In addition, overexpression of PKCζ leads to cardiac hypertrophy and sudden death.19 Thus, hyperactivation or overexpression of PKCζ is an inducible factor for cardiac hypertrophy and failure. In contrast, PKCζ protects the heart from apoptosis induced by ischemia and reperfusion injury,20 and PKCζ is required for cardiomyocyte survival and epidermal hyperplasia, and cytokine overproduction.10–13

Subject Category: Experimental Medicine

1Laboratory of Genome and Biosignals, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan; 2CREST, JST, Kawaguchi, Saitama, Japan and 3Department of Molecular and Cellular Pharmacology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan

*Corresponding author: K Fukami, Laboratory of Genome and Biosignals, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, 192-0392 Tokyo, Japan. Tel: +81 42 676 7214; Fax: +81 42 676 7214; E-mail: kfukami@toyaku.ac.jp

Keywords: PLC; cardiomyocyte; cardiac dilation; remodeling

Abbreviations: PLC, phospholipase C; PKC, protein kinase C; siRNA, small interfering RNA; cDKO, conditional double knockout; DCM, dilated cardiomyopathy; PIP2, phosphatidylinositol 4,5-bisphosphate; IP3, 1,4,5-trisphosphate; E, embryonic day; EF, ejection fraction; FS, fractional shortening; TUNEL, terminal transferase dUTP nick end labeling; PMA, phorbol 12-myristate 13-acetate

Received 22.7.13; revised 23.1.14; accepted 26.3.14; Edited by G Condorelli
cardiac remodeling. The conventional PKC isozymes, PKC\(\alpha\) and PKC\(\beta_1\) are activated by calcium and diacylglycerol, whereas the novel PKC isozymes, PKC\(\epsilon\) and PKC\(\theta\) require diacylglycerol but do not require calcium. Their distinct activation mechanisms may be involved in the difference in physiological functions between conventional and novel PKC isozymes. Both conventional and novel PKC isozymes are activated downstream of PLC. However, mice that lack either PLC\(\delta_1\) or PLC\(\delta_3\) do not show apparent cardiac abnormalities. As PLC\(\delta_1\) and PLC\(\delta_3\) share high sequence homology, one gene product likely compensates for the lack of the product of the other gene in mice. Unfortunately, the simultaneous loss of PLC\(\delta_1\) and PLC\(\delta_3\) results in embryonic lethality because of excessive apoptosis of placental trophoblasts and impaired vascularization of the placenta, which hampered our investigation into the roles of the PLC\(\delta_1\) and PLC\(\delta_3\) genes in the cardiovascular systems in adult animals. In this study, we generated and analyzed mice that lack PLC\(\delta_1\) and PLC\(\delta_3\) with extra-embryonic PLC\(\delta_1\) expression and found that the simultaneous loss of PLC\(\delta_1\) and PLC\(\delta_3\) results in DCM-like phenotypes that are associated with excessive apoptosis of cardiomyocytes.

**Results**

**Extra-embryonic expression of PLC\(\delta_1\) rescued embryonic lethality of PLC\(\delta_1\)\(^{-/-}\) PLC\(\delta_3\)\(^{-/-}\) mice.** We previously generated PLC\(\delta_1\)\(^{-/-}\) PLC\(\delta_3\)\(^{-/-}\) mice (DKO mice) and found that they died in utero at embryonic day (E) 11.5–13.5 because of excessive apoptosis of trophoblasts and placental vascular abnormalities. This embryonic lethality hampered our investigation into the roles of the PLC\(\delta_1\) and PLC\(\delta_3\) genes in the embryo proper by using Meox2\(^{Cre/-}\) mice, which express Cre recombinase in the embryo proper but not in extra-embryonic tissues, such as the placenta and yolk sac. Using these mice, we further generated Meox2\(^{Cre/-}\) PLC\(\delta_1\)\(^{m/m}\) PLC\(\delta_3\)\(^{m/m}\) (cDKO mice) (Figure 1a). In contrast to DKO mice, the cDKO mice exhibited normal labyrinth architecture and vascularization in the placenta (Figure 1b). The cDKO mice were born at the expected Mendelian ratio (Table 1), which indicated that the simultaneous loss of PLC\(\delta_1\) and PLC\(\delta_3\) in the embryo proper did not result in embryonic lethality. We then confirmed that PLC\(\delta_1\) and PLC\(\delta_3\) are essential for the survival of the embryo proper.

![Figure 1](image.png)

**Figure 1**  
(cDKO mice were born but died prematurely. (a) PCR analysis of genomic DNA from the tails of Meox2\(^{+/+}\) PLC\(\delta_1^{m/m}\) PLC\(\delta_3^{m/m}\) (Meox2\(^{+/+}\)\(\delta_1^{m/m}\)\(\delta_3^{m/m}\)), Meox2\(^{+/+}\) PLC\(\delta_1^{m/m}\) PLC\(\delta_3^{+/+}\) (Meox2\(^{+/+}\)\(\delta_1^{m/m}\)\(\delta_3^{+/+}\)), Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{m/m}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{m/m}\)), and Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{+/+}\)) mice. W, M, and F indicate PCR products from wild-type, mutant, and floxed alleles, respectively. (b) Hematoxylin and eosin staining of the labyrinth area of the placenta from Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{+/+}\)), Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{m/m}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{m/m}\)), and Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{+/+}\)) embryos at E13.5. The arrows indicate embryonal vessels and the arrowheads indicate maternal vessels. Scale bar, 25 \(\mu\)m. (c) Immunoblotting of PLC\(\delta_1\), PLC\(\delta_3\), and tubulin in tissues from Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{+/+}\)) and Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{+/+}\)) mice. (d) Survival curves for Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{+/+}\)), Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{m/m}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{m/m}\)), Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{+/+}\)), and Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\) (Meox2\(^{+/+}\)\(\delta_1^{+/+}\)\(\delta_3^{+/+}\)) mice (Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\), n = 70; Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{m/m}\), n = 64; Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\), n = 62; and Meox2\(^{+/+}\) PLC\(\delta_1^{+/+}\) PLC\(\delta_3^{+/+}\), n = 62).
Cardiac functions of PLCδ1 and PLCδ3
Y Nakamura et al

Table 1 Genotyping of offspring from Meox2 +/− PLCδ1+/−PLCδ3+/− x Meox2cre+/− PLCδ1−/−PLCδ3+/− mating

| Meox2+/− | Meox2cre+/− |
|----------|-------------|
| δ1+/−, δ3+/− | δ1+/−, δ3+/− |
| No. with genotype | 70 (64) | 64 (64) | 62 (64) | 62 (64) | 258 |

The numbers in parentheses were calculated from the expected Mendelian frequencies

Table 1

Neither PLCδ1 nor PLCδ3 was expressed in the tissues of the adult cDKO mice, which indicated that mice that lacked both PLCδ1 and PLCδ3 were successfully obtained (Figure 1c). Loss of either PLCδ1 or PLCδ3 did not affect the postnatal survival rate. However, about half of the cDKO mice died in less than 2 weeks after birth (Figure 1d), which indicated that the simultaneous loss of PLCδ1 and PLCδ3 results in premature death.

cDKO mice had hearts with abnormal morphologies and impaired function. We next analyzed cDKO mice that survived the first 4 weeks. Although surviving cDKO mice had a normal life span, they had smaller body sizes than did the mice that lacked either PLCδ1 or PLCδ3. Morphological analysis revealed that Meox2+/− PLCδ1+/− PLCδ3+/−, Meox2cre+/− PLCδ1+/− PLCδ3+/−, and Meox2+/− PLCδ1+/− PLCδ3+/− mice had normal-shaped hearts, whereas the cDKO mice had irregular-shaped hearts with white foci after 6 weeks of age (arrows in Figure 2a). In addition, the heart weight/tibial length ratio was significantly increased for the cDKO mice (Figure 2b). Although heart weights were not significantly increased, cDKO mice have smaller body and their tibial length was shorter than that of control mice, resulting in increase in heart weight/tibial length ratio. This increase in the ratio was not observed in other organs, such as liver, indicating that the increase in the heart weight/tibial length ratio was specific. Because the cDKO hearts showed abnormal morphologies, we examined their cardiac function by performing echocardiography (Figures 2c and d). The ejection fraction (EF) and fractional shortening (FS) are echocardiographic indicators of overall cardiac function. There were no significant differences in the EF and FS among all genotypes at 4 weeks of age (Figure 2c). After 6 weeks, both the FS and EF were significantly decreased in the cDKO mice (Figure 2c). These results suggest that the cDKO mice had impaired cardiac function, and that this impairment occurred between 4 and 6 weeks of age, which was concomitant with their morphological abnormalities (Figure 2a). In addition to the EF and FS, the end-systolic volume and end-diastolic volume were increased in the cDKO hearts (Figure 2c), which indicated that the cDKO mice showed DCM-like phenotypes. Because the induction of natriuretic peptides ANP and BNP is a marker of cardiac failure, we measured the mRNA levels of ANP and BNP in the cDKO hearts. At 8 weeks of age, both the ANP and BNP were upregulated in the cDKO hearts (Figure 2e). The cDKO hearts also exhibited the α→β isoform switch of myosin heavy chain (MHC) and an increased ratio of β-MHC/α-MHC expression, which are typical features of heart failure at 8 weeks of age (Figure 2e). Thus, the cDKO hearts showed cardiac dysfunction and upregulation of cardiac failure markers. It is possible that the cardiac abnormalities in the cDKO mice were attributable to right ventricle cardiomyopathy. Therefore, we examined whether abnormal structure of the right ventricle and subsequent structural changes in the lungs were observed in cDKO mice. There were no apparent changes in the structure of the lungs or the right ventricle in cDKO mice, suggesting that the cardiac phenotypes were not caused by right ventricle cardiomyopathy (Supplementary Figure S1). In our mating strategy, Meox2+/− PLCδ1+/− PLCδ3+/−, Meox2cre+/− PLCδ1+/− PLCδ3+/−, and Meox2+/− PLCδ1+/− PLCδ3−/− mice were obtained as littermates of cDKO (Meox2cre+/− PLCδ1+/− PLCδ3−/−) mice (Table 1). Any cardiac abnormalities that were observed in the cDKO mice were not observed in the littermates with other genotypes. Therefore, the littermates of the cDKO mice were used as a control in subsequent experiments, irrespective of their genotypes.

Simultaneous loss of PLCδ1 and PLCδ3 caused cardiac fibrosis and hypertrophy. Because the cDKO mice showed cardiac dysfunction, we examined detailed histological structures of their hearts. Hematoxylin and eosin (HE) staining revealed that the cDKO hearts had fibrotic lesions (Figure 3a). Although these fibrotic lesions were not observed at 4 weeks of age, fibrosis was observed in the ventricular walls after 6 weeks of age (Figure 3a). We also stained collagen fibers by performing trichrome staining and found that the ventricular walls exhibited strong positive staining after 6 weeks of age (means ± S.E.M. fibrosis-to-total ventricular area ratios, 0.0074 ± 0.00096 in 6-week-old Meox2+/− PLCδ1+/− PLCδ3+/−, 0.087 ± 0.0095 in 6-week-old cDKO, 0.0071 ± 0.0011 in 12-week-old Meox2+/− PLCδ1+/− PLCδ3+/−, and 0.094 ± 0.0075 in 12-week-old cDKO mice; n = 3, for each) (Figure 3b). We further confirmed the occurrence of cardiac fibrosis at the molecular level by assessing the expression of fibrosis-related genes. Real-time reverse transcriptase PCR (RT-PCR) revealed that extracellular matrix components, such as fibronectin and collagen (Col1A1 and Col3A1), were upregulated in the cDKO hearts (Figure 3c and Supplementary Table S1). We also observed the upregulation of pro-fibrotic factors, such as connective tissue growth factor (CTGF), transforming growth factor (TGF)/β2, and TGF/β3 in the cDKO hearts (Figure 3c and Supplementary Table S1). The markers for cardiac remodeling that were associated with cardiac fibrosis, such as tissue inhibitors of metalloproteinase 1 (TIMP-1) and matrix metalloproteinase 2 (MMP-2), were also upregulated in the cDKO hearts (Figure 3c and Supplementary Table S1). These results indicate that the cDKO hearts showed cardiac fibrosis at both the histological and molecular levels.

Because elevated blood pressure may be a cause for cardiac failure and fibrosis, we measured the blood pressures of the cDKO mice. The cDKO mice did not show remarkable changes in their systolic blood pressure when compared with the control mice (Figure 3d and Supplementary Table S2), which indicated that their cardiac fibrosis was not caused by hypertension. Apart from cardiac fibrosis, the cDKO cardiomyocytes were hypertrophic.
Figure 2  cDKO mice had hearts with abnormal morphologies and impaired functions. (a) Gross appearance of hearts from Meox2+/+ PLCδ1−/− PLCδ3−/− (Hetero), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ1KO), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ3KO), and Meox2−/− PLCδ1−/− PLCδ3−/− (cDKO) mice at 4, 6, 8, and 12 weeks of age. Scale bar, 2 mm. The boxed areas in the cDKO hearts at 6, 8, and 12 weeks are magnified in the right panels. The arrows indicate white foci. (b) Heart (upper panel) or liver (lower panel) weight-to-tibial length ratios of Meox2+/+ PLCδ1−/− PLCδ3−/− (hetero), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ1KO), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ3KO), and Meox2−/− PLCδ1−/− PLCδ3−/− (cDKO) mice. Mean ± S.E.M. (hetero, n = 3; PLCδ1KO, n = 6; PLCδ3KO, n = 6; and cDKO, n = 5). (c) Quantitative data of echocardiographic measurements. Echocardiograms were measured in Meox2+/+ PLCδ1−/− PLCδ3−/− (hetero), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ1KO), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ3KO), and Meox2−/− PLCδ1−/− PLCδ3−/− (cDKO) mice at 4, 6, 8, and 12 weeks of age. Mean ± S.E.M. (hetero, n = 6; PLCδ1KO, n = 6; PLCδ3KO, n = 7; and cDKO, n = 5 at each time point). EF, ejection fraction; FS, fraction shortening; ESV, end-systolic volume; and EDV, end-diastolic volume. (d) Representative M-mode echocardiograms of Meox2+/+ PLCδ1−/− PLCδ3−/− (hetero), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ1KO), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ3KO), and Meox2−/− PLCδ1−/− PLCδ3−/− (cDKO) mice at 8 weeks of age. (e) mRNA expression or ratios of cardiac failure markers in the hearts of Meox2+/+ PLCδ1−/− PLCδ3−/− (hetero), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ1KO), Meox2−/− PLCδ1−/− PLCδ3−/− (PLCδ3KO), and Meox2−/− PLCδ1−/− PLCδ3−/− (cDKO) mice at 8 weeks of age. The results are listed in arbitrary units (expression or ratio in hetero = 1). Mean ± S.E.M. (hetero, n = 6; PLCδ1KO, n = 3; PLCδ3KO, n = 3; and cDKO, n = 4). Statistical significance was assessed using Tukey–Kramer’s post hoc test. *P<0.05 and **P<0.01.
Although the cell size remained unchanged at 2 and 4 weeks of age, the cardiomyocyte cross-sectional areas increased at 12 weeks of age (Figure 3e). Thus, cDKO hearts showed signs of pathological remodeling, such as cardiac fibrosis and hypertrophy, which is often associated with DCM.

Simultaneous depletion of PLCδ1 and PLCδ3 caused cardiomyocyte apoptosis. Because apoptotic loss of cardiomyocytes leads to cardiac dysfunction and remodeling, we determined the number of apoptotic cells in the heart ventricles of cDKO mice that were 4 weeks of age before the onset of these cardiac abnormalities. A terminal transferase dUTP nick end labeling (TUNEL) assay revealed that apoptotic cardiomyocytes were easily found in the cDKO ventricles, whereas apoptotic cardiomyocytes were rarely observed in control ventricles (means ± S.E.M. 100 cells per section). Statistical significance was assessed using Student’s t-test. *P<0.05 and **P<0.01.

Figure 3  cDKO mice showed cardiac fibrosis. (a, b) Hematoxylin and eosin (a) and Masson trichrome (b)-stained sections from the left ventricles of control (Meox2+/+ PLCδ1fl/fl PLCδ3+/−) and cDKO mice at 4, 6, 8, and 12 weeks of age. The arrows indicate fibrotic areas (blue). Scale bar, 100 μm. (c) mRNA expression of cardiac fibrosis markers in the hearts of cDKO mice at 8 weeks of age. The results are listed in arbitrary units (expression in control mice = 1). Mean ± S.E.M. (control, n = 12; cDKO, n = 4). (d) Systolic, diastolic blood pressure of 4- or 6-week-old control and cDKO mice. Mean ± S.E.M. (4 weeks, male: control, n = 9; cDKO, n = 4; 4 weeks, female: control, n = 9; cDKO, n = 3; 6 weeks, male: control, n = 10; cDKO, n = 4; 6 weeks, female, control, n = 11; and cDKO, n = 4). (e) Hematoxylin and eosin-stained sections from left ventricles of control (Meox2+/+ PLCδ1fl/fl PLCδ3+/−) and cDKO mice at 12 weeks of age. Scale bar, 50 μm. Quantitative data of myocyte cross-sectional areas are also shown. Mean ± S.E.M. 100 cells per section. (Control, n = 3 and cDKO, n = 3). Statistical significance was assessed using Student’s t-test. *P<0.05 and **P<0.01.
for TUNEL-positive cells, 0.051 ± 0.021% in Meox2+/+ PLC1Δfl−/− PLC3Δfl−/−, 0.050 ± 0.0031% in Meox2Δm+/+ PLC1Δfl−/− PLC3Δfl−/−, 0.057 ± 0.0047% in Meox2+/+ PLC1Δfl−/− PLC3Δfl−/−, and 0.14 ± 0.046% in cDKO mice; n = 3 for each) (Figures 4a and b). There were neither apparent structural abnormalities nor an increase in the number of TUNEL-positive cells in the hearts of E17.5 embryos, compared with those in the hearts of control embryos, strongly suggesting that PLC1Δ1 and PLC3Δ3 were not required for cardiac protection during normal development (Supplementary Figure S2). We also confirmed that mRNA expression of the proapoptotic gene Bax was significantly increased in the cDKO hearts at 4 weeks of age (Figure 4c). In addition, western blotting showed that levels of proapoptotic proteins, Bax and Bad, were increased in cDKO hearts, whereas that of antiapoptotic protein, Bcl-2, were decreased in the cDKO hearts (Figure 4d). Thus, the cDKO mice showed excessive apoptosis of cardiomyocytes.

We further carried out siRNA-mediated simultaneous knockdown of PLC1Δ1 and PLC3Δ3 in H9c2 rat cardiomyoblasts with two distinct siRNA that target PLC1Δ1 and PLC3Δ3, and induced the differentiation of H9c2 cells into cardiomyocytes with low-serum differentiation-promoting medium. Western blotting revealed that the amounts of PLC1Δ1 and PLC3Δ3 proteins were decreased in the differentiated-H9c2 cells by the introduction of the siRNA (Figure 5a), which indicated the effective knockdown of PLC1Δ1 and PLC3Δ3. The simultaneous knockdown of PLC1Δ1 and PLC3Δ3 resulted in cell spreading (Figure 5b), which suggests that PLC1Δ1 and PLC3Δ3 regulate the morphology of cardiomyocytes. Unexpectedly, similar morphological changes were observed by the single knockdown of PLC3Δ3 (Figure 5b), which suggests that PLC3Δ3

![Figure 4](image1.png)

**Figure 4** cDKO mice showed excessive apoptosis of cardiomyocytes. (a) TUNEL staining (red) of hearts from 4-week-old control (Meox2+/+ PLC1Δfl−/− PLC3Δfl−/−) and cDKO mice. Hoechst (blue) was used for nuclear staining. The arrowheads indicate TUNEL-positive nuclei. The right-hand panels are overlay images of the left field and TUNEL-positive cells. Scale bar, 25 μm. (b) Population of TUNEL-positive cells in the hearts of 4-week-old control (Meox2+/+ PLC1Δfl−/− PLC3Δfl−/−) and cDKO mice. Mean ± S.E.M. (control, n = 4; cDKO, n = 3). (c) mRNA expression of the proapoptotic gene Bax in the hearts of control (Meox2+/+ PLC1Δfl−/− PLC3Δfl−/−, n = 2; Meox2Δm+/+ PLC1Δfl−/− PLC3Δfl−/−, n = 2; Meox2+/+ PLC1Δfl−/− PLC3Δfl−/−, n = 3) and cDKO mice at 4 weeks of age. The results are listed in arbitrary units (expression in control mice = 1). Mean ± S.E.M. (control, n = 7; cDKO, n = 4). Statistical significance was assessed using Student's t-test. *P < 0.05 and **P < 0.01. (d) Immunoblotting of Bax, Bad, Bcl-2, and GAPDH in Meox2+/+ PLC1Δfl−/− PLC3Δfl−/− (hetero), Meox2Δm+/+ PLC1Δfl−/− PLC3Δfl−/− (PLC1Δ1KO), Meox2+/+ PLC1Δfl−/− PLC3Δfl−/− (PLC1Δ3KO), and Meox2+/+ PLC1Δfl−/− PLC3Δfl−/− (cDKO) hearts at 8 weeks of age.

![Figure 5](image2.png)

**Figure 5** siRNA-mediated simultaneous silencing of PLC1Δ1 and PLC3Δ3 increased apoptosis in a cardiomyocyte cell line. (a) Immunoblotting of PLC1Δ1, PLC1Δ3, and β-actin in differentiated-H9c2 cells that were transfected with scrambled, PLC1Δ1-targeting (#1 and #2), or PLC1Δ3-targeting (#1 and #2) siRNA. (b) Morphologies of differentiated-H9c2 cells with the indicated siRNA. The cells were stained with phalloidin (green) and Hoechst (blue). Scale bar, 25 μm. (c-f) Population of H9c2 cells with shrunken nuclei under normal culture conditions (c and d) or oxidative stress conditions (e and f). The arrows indicate shrunken nuclei. Scale bar, 25 μm. Mean ± S.E.M. (g-j) Population of H9c2 cells with TUNEL-positive nuclei under normal culture conditions (g and h) or oxidative stress conditions (i and j). The arrows indicate TUNEL-positive nuclei. Scale bar, 25 μm. Mean ± S.E.M. (b-j) The data were obtained with scrambled, PLC1Δ1-targeting (#1), and/or PLC1Δ3-targeting (#1) siRNA. Similar results were obtained with scrambled, PLC1Δ1-targeting (#2), and/or PLC1Δ3-targeting (#2) siRNA. Statistical significance was assessed using Tukey–Kramer’s post hoc test. *P < 0.05 and **P < 0.01.
Cardiac functions of PLCα1 and PLCα3

Y Nakamura et al

Cell Death and Disease
downregulation is, in contrast to in vivo case, sufficient for the induction of abnormal morphology of cardiomyocytes in vitro. In addition to morphological changes, simultaneous downregulation of PLCδ1 and PLCδ3 induces nuclear shrinking, which is a typical feature of apoptosis under normal culture conditions (Figures 5c and d) and oxidative stress conditions (Figures 5e and f). We further confirmed the apoptosis of cardiomyocytes by TUNEL staining and found that simultaneous silencing of PLCδ1 and PLCδ3 increased the number of TUNEL-positive cells under normal culture conditions (Figures 5g and h) and oxidative stress conditions (Figures 5i and j). Although the extent was milder than the
extent in double-knockdown cells, single knockdown of PLC1/3 also induced apoptosis. Taken together, these findings suggest that simultaneous depletion of PLC1/1 and PLC1/3 increased the apoptosis of cardiomyocytes in a cell-intrinsic manner.

Simultaneous depletion of PLC1/1 and PLC1/3 impaired the activation of PKCζ. Increased apoptosis in the cDKO heart could be caused by impairment of survival signals and activation of proapoptotic signals. Western blotting revealed that activation of Akt was impaired in cDKO hearts and in H9c2 cells under oxidative stress conditions, indicating that the survival signal was impaired by a combined loss of PLC1/1 and PLC1/3 (Figures 6a and b). In contrast, the combined loss of PLC1/1 and PLC1/3 increased the level of activated caspase 9 (Figure 6a), indicating that a proapoptotic signal was activated in the cDKO heart. PKC isozymes have critical roles in the maintenance of cardiac structure and functions. As active PKC isozymes are reported to be present in the particulate fraction of the heart,21 we examined the amounts of PKC isozymes in particulate fractions of the heart at 6 weeks of age. The amount of PKCζ was decreased in the particulate fraction of the cDKO heart compared with the control heart (Figure 6c and Supplementary Figure S3). In contrast, simultaneous loss of PLC1/1 and PLC1/3 did not cause remarkable changes in the levels of PKCα, PKCβ1, and PKCε in the particulate fraction (Figure 6c). Impaired activation of PKCζ was also observed in PLC1/1/PLC1/3 double-knockdown H9c2 cells by examining the amount of phosphorylated PKCζ (Figure 6d). Consistent with mild induction of apoptosis by single knockdown of PLC1/3 (Figures 5g–j), the amount of phosphorylated PKCζ was slightly decreased in PLC1/3 single-knockdown H9c2 cells (Figure 6d). These results indicate that simultaneous depletion of PLC1/1 and PLC1/3 separately impaired the activation of PKCζ. Interestingly, siRNA-mediated silencing of PKCζ in H9c2 cells resulted in morphological changes and increased apoptosis, in a manner similar to the combined silencing of PLC1/1 and PLC1/3 (Figures 6e–h). Furthermore, the numbers of cells with shrunk nuclei were decreased by treating PLC1/1/PLC1/3 double-knockdown H9c2 cells with a PKC activator, phorbol 12-myristate 13-acetate (PMA) (Figure 6i). These results strongly suggest that PKCζ is involved in the morphological changes and high apoptosis caused by the simultaneous knockdown of PLC1/1 and PLC1/3.

Discussion

In this study, we demonstrated that the simultaneous loss of PLC1/1 and PLC1/3 induces cardiac fibrosis, hypertrophy of cardiomyocytes, so-called pathological remodeling, and cardiomyopathy. In addition, we found that double silencing of PLC1/1 and PLC1/3 resulted in morphological changes in H9c2 cells, which suggests that these enzymes contribute to the maintenance of the shape of cardiomyocytes. Therefore, deletion of these enzymes likely contributes to the induction of cardiomyocyte hypertrophy. Furthermore, we found that the absence of both PLC1/1 and PLC1/3 causes enlargement of the left ventricular cavity, that is, a DCM-like phenotype. Given that the simultaneous loss of PLC1/1 and PLC1/3 in the embryo proper did not result in embryonic lethality and that the number of apoptotic cells did not apparently increase in the cDKO embryos, PLC1/1 and PLC1/3 are specifically required by the adult heart and are dispensable during cardiac development in the embryo.

Cardiomyocyte dropout was often followed by cardiac fibrosis. Predating other cardiac abnormalities, excessive apoptosis was observed in cDKO cardiomyocytes as early as 4 weeks of age, which suggests that excessive apoptosis seems to be a cause for cardiac fibrosis, at least partially. Interestingly, we have reported that simultaneous loss of PLC1/1 and PLC1/3 results in excessive apoptosis in placental trophoblasts,22 which indicates that PLC1/1 and PLC1/3 regulate cell survival in both cardiomyocytes and trophoblasts. Unexpectedly, the silencing of merely PLC1/3 leads to a modest increase in apoptotic cells in H9c2 cells despite no apparent apoptotic phenotypes in the PLC1/3 KO heart in vivo. Cardiomyocytes may be protected from apoptosis in an in vivo environment by unknown mechanisms, and the loss of PLC1/3 is insufficient to induce apoptosis.

The mechanisms by which loss of PLC1/1 and PLC1/3 causes cardiac abnormalities remain to be fully elucidated. Loss of PKCζ in mice resulted in cardiac abnormalities, including a reduction in contractile performance, increased end-systolic volume, cardiac fibrosis, hypertrophy of cardiomyocytes, and apoptosis of cardiomyocytes.21 All of these cardiac abnormalities were observed in the cDKO mice. In addition, loss of PKCζ leads to inhibition of Akt and activation of caspase 9, as does the combined loss of PLC1/1 and PLC1/3.21 PLC1/1 and PLC1/3 generate diacylglycerol, which is an activator for PKCζ and simultaneous depletion of PLC1/1 and PLC1/3 impaired the activation of PKCζ. Therefore, insufficient activation of PKCζ is likely to be a cause for cardiac abnormalities in cDKO mice. Accordingly, the
silencing of PKC\(\beta\) leads to a partial phenocopy of the combined silencing of PLC\(\alpha\)1 and PLC\(\beta\)3 in H9c2 cells. In addition to PKC\(\beta\), lack of PKC\(\delta\) resulted in interstitial fibrosis when the mice were subjected to pressure overload by transverse aortic constriction.\(^{24}\) In addition, PKC\(\delta\) has a protective role against cardiomyocyte apoptosis during cardiac ischemia/reperfusion injury.\(^{20}\) However, simultaneous loss of PLC\(\alpha\)1 and PLC\(\beta\)3 did not affect the activation status of PKC\(\delta\). PLC\(\alpha\)1 and PLC\(\beta\)3 may specifically regulate the activation of PKC\(\beta\) isoforms by unknown mechanisms. In addition to PKC, PLC activation results in the elevation of the intracellular calcium ion concentration \([Ca^{2+}]_i\) and activates calcium-dependent downstream molecules. In cardiomyocytes, cardiac excitation-contraction coupling (ECC) occurs through \(Ca^{2+}\) -induced \(Ca^{2+}\) release channel (CICR). Although ryanodine receptors are the primary \(Ca^{2+}\) release channel that mediates CICR during cardiac ECC, the IP\(_3\) receptor \((\text{IP}_3\text{R})\) \(Ca^{2+}\) release channel is also expressed in cardiomyocytes.\(^{25,26}\) Recent evidence suggests that the activation of \(\text{IP}_3\text{R}\) may modulate ECC.\(^{27,28}\) Therefore, simultaneous loss of PLC\(\alpha\)1 and PLC\(\beta\)3 may result in abnormal \(Ca^{2+}\) handling in cardiomyocytes, thereby leading to cardiac abnormalities in cDKO mice. Loss of calcineurin A\(\beta\), which is a calcium-dependent serine-threonine phosphatase, increases the number of apoptotic cardiomyocytes and cardiac fibrosis in mice with DCM.\(^{29,30}\)

Given that our cDKO mice showed a DCM-like phenotype, calcineurin A\(\beta\) may also be involved in cardiac abnormalities in cDKO mice. In addition to PKC and \([Ca^{2+}]_i\), the PLC substrate PIP\(_2\) has roles in cardiac muscle relaxation between contractions by positively regulating a Na\(^+\)/Ca\(^{2+}\) exchanger, which removes \(Ca^{2+}\) into the extracellular space.\(^{31}\) Therefore, impaired hydrolysis of PIP\(_2\) may also contribute to cardiac abnormalities in cDKO mice. The findings of this study suggest that PLC\(\alpha\)1 and PLC\(\beta\)3 are possible therapeutic targets for DCM and cardiac remodeling that leads to heart failure. Future work will determine whether the expression and/or activity of PLC\(\alpha\)1 and PLC\(\beta\)3 in patients with DCM and/or heart failure are decreased.

Materials and Methods

Mice. PLC\(\alpha\)1\(^{-/-}\) mice and PLC\(\beta\)3\(^{-/-}\) mice (Acc. No. CDB0552K; http://www.cdb.niken.jp/arg/mutant%20mice%20list.html) were produced as described previously.\(^{13,22}\) Mice were 8-12 weeks old at the time of analysis. Genetic markers were validated by PCR. Mice were housed in apathic state by culturing them in Dulbecco’s modified Eagle’s medium (DMEM) that was supplemented with 10% fetal bovine serum at 37 \(^\circ\)C in a humidified atmosphere with 5% CO\(_2\) using rat PLC\(\beta\)3, and rat PKC\(\delta\)1 was purchased from Invitrogen (Stealth RNAi) and transfected with Lipofectamine RNAiMAX (Life Technologies) at 40 nM. Two individual non-overlapping Stealth RNAi duplexes per target were used for all experiments and closely similar results were obtained with these Stealth RNAi duplexes. Differentiation into cardiomyocytes was induced by culturing H9c2 cells with 1% FBS, cell death was determined by staining with Hoechst 33342 and PI live cell stain (Invitrogen). Hoechst staining was observed under a BX51 microscope (Olympus, Tokyo, Japan).

TUNEL assay. TUNEL assay was performed on paraffin sections with an In Situ Cell Death Detection Kit, TMRed (Roche, Basel, Switzerland). Counter-staining was performed with Hoechst 33258 (Life Technologies, Carlsbad, CA, USA). Sections were observed under a BX-7000 microscope (Keyence, Osaka, Japan).

Culturing and siRNA-mediated gene silencing of H9c2 cells. The H9c2 rat cardiomyoblast cell line was purchased from DS Pharma Biomedical (Osaka, Japan). The cells were maintained in a proliferative state by culturing them in Dulbecco’s modified Eagle’s medium (DMEM) that was supplemented with 10% fetal bovine serum at 37 \(^\circ\)C in a humidified atmosphere with 5% CO\(_2\). RNAi against rat PLC\(\alpha\)1, rat PLC\(\beta\)3, and PLC\(\delta\)1 was purchased from Invitrogen (Stealth RNAi) and transfected with Lipofectamine RNAiMAX (Life Technologies) at 40 nM. Two individual non-overlapping Stealth RNAi duplexes per target were used for all experiments and closely similar results were obtained with these Stealth RNAi duplexes. Differentiation into cardiomyocytes was induced by changing the medium to DMEM with 1% FBS for 72 h. For PMA treatment, H9c2 cells were treated with 160 nM PMA for 48 h. In some experiments, H9c2 cells were treated with 100 \(\mu\)M H_2O_2 for 1 h. After a further 24 h of culturing with DMEM with 1% FBS, cell death was determined by staining with Hoechst 33342 (Dojin, Japan) or by using an In Situ Cell Death Detection Kit, TMRed (Roche). The cells were observed under a BX-7000 microscope (Keyence, Osaka, Japan).

Echocardiography. Echocardiography was performed as described previously.\(^{32}\) Mice were anesthetized with an intraperitoneal injection of 25 mg/kg pentobarbital (Sigma). After anesthesia, the left hemithorax of each mouse was shaved. The animals were pre-warmed with a panel heater to maintain their rectal temperature at 37 \(^\circ\)C during the determination of cardiac parameters by echocardiography. Transthoracic echocardiography was performed using ProSound 5500R (Aloka, Tokyo, Japan) with a 13-MHz linear transducer for mice in a phased array format, which offered a lateral resolution of 0.35 mm and an axial resolution of 0.25 mm, real-time digital acquisition, storage, and review capabilities. Each cardiac parameter was calculated from the echocardiogram as described previously.\(^{32}\)

| Table 2 Real-time reverse-transcription PCR primers |
|----------------------------------------|
| ANP | 5'-TCGCTTTGGGCTTTGGGCTG-3' |
| BNP | 5'-GCCACCCGAGCAGGCTTGC-3' |
| CTGF | 5'-CAAGTGGTTCAGTTTTCAGTC-3' |
| Col1A1 | 5'-AAACCCAGATGCTTGCAGCTGA-3' |
| Col3A1 | 5'-TGATAGGCTTGTATGGTGACC-3' |
| MMP-2 | 5'-GGGCTAGTATGAGAAGATCCT-3' |
| TIMP-1 | 5'-AAGTCCGGACGGTCTAGGA-3' |
| GAPDH | 5'-TGTCATCTACTGCTGGACC-3' |

Histochemistry. For histological analyses, placenta or hearts were fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Sections (5 \(\mu\)m thick) were stained with HE. Trichrome staining was performed with a Trichrome Stain (Masson) Kit (Sigma, St Louis, MO, USA) according to the manufacturer’s instructions. Sections were examined under a BX51 microscope (Olympus, Tokyo, Japan).

Histology. For histological analyses, placenta or hearts were fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Sections (5 \(\mu\)m thick) were stained with HE. Trichrome staining was performed with a Trichrome Stain (Masson) Kit (Sigma, St Louis, MO, USA) according to the manufacturer’s instructions. Sections were examined under a BX51 microscope (Olympus, Tokyo, Japan).

Histology. For histological analyses, placenta or hearts were fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Sections (5 \(\mu\)m thick) were stained with HE. Trichrome staining was performed with a Trichrome Stain (Masson) Kit (Sigma, St Louis, MO, USA) according to the manufacturer’s instructions. Sections were examined under a BX51 microscope (Olympus, Tokyo, Japan).
Measurement of blood pressure. Systolic blood pressure of non-anesthetized mice was measured by tail-cuff blood pressure measurement using a computerized CODA high-throughput noninvasive BP acquisition system (Kent Scientific Corp., Torrington, CT, USA), in accordance with the manufacturer’s instructions. Briefly, the mice were placed in a warmed chamber. Cuffs were placed around the mouse tail to measure arterial systolic pressure. Three to five readings were recorded for each animal. Measurements were repeated in the event of animal movement or weak pressure/flow recordings.

Preparation of subcellular protein fractions from hearts. Preparation of subcellular protein fractions from hearts was performed as described.21 Briefly, hearts were homogenized in homogenization buffer (20 mM Tris at pH 7.5, 2 mM EGTA, 2 mM EDTA, 250 mM sucrose, 5 mM DTT, and Complete Protease Inhibitor Cocktail Tablets (Roche)) and incubated for 30 min on ice. The samples were then spun at 100 000 g for 30 min at 4 °C. The supernatant was stored as the cytosolic fraction, whereas the remaining pellet was further suspended in homogenization buffer containing 0.1% Triton X-100 and incubated for 30 min on ice. Then, the samples were spun at 100 000 g for 30 min at 4 °C and the remaining supernatant was stored as the particulate fraction. An equal amount of each sample was subjected to immunoblotting.

Antibodies. The following antibodies were used for immunoblotting: PLCδ1, PKCα, caveolin1, Bax (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); PKCδ1, PKCδ3, Caveolin1, Bax (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA); and PKCδ3, Thr308-p-PKCδ, Bad, Bcl2, Akt, Ser473-p-Akt, ERK, p-ERK, cleaved Caspase 9, Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cell Signaling Technology Inc., Danver, MA, USA).

Conflict of Interest The authors declare no conflict of interest.

Acknowledgements. We thank Ms I. Ishikawa, Mr K Kaneko, Ms K Shiratori, Dr F Iioh, and Dr T Watanabe for their technical assistance and fruitful discussions. This work was supported by the Funding Program for Next Generation World-Leading Researchers, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and the Takeda Science Foundation to K.F., as well as a Grant-in-Aid for Young Scientists (B), Ono Medical Research Foundation, and The World-Leading Researchers, the Mochida Memorial Foundation for Medical and Pharmaceutical Research.

Supplementary Information accompanies this paper on Cell Death and Disease website (http://www.nature.com/cddis)